Atamestane
Atamestane (developmental code name SH-489), also known as metandroden, as well as 1-methylandrosta-1,4-diene-3,17-dione, is a steroidal aromatase inhibitor that was studied in the treatment of cancer.[1] It blocks the production of estrogen in the body. The drug is selective, competitive, and irreversible in its inhibition of aromatase.[2]
Clinical data | |
---|---|
Other names | SH-489; Metandroden; 1-Methylandrosta-1,4-diene-3,17-dione |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H26O2 |
Molar mass | 298.426 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
See also
- Boldione (androsta-1,4-diene-3,17-dione)
References
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 794–. ISBN 978-1-4757-2085-3.
- el Etreby MF (March 1993). "Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review". The Journal of Steroid Biochemistry and Molecular Biology. 44 (4–6): 565–72. doi:10.1016/0960-0760(93)90260-4. PMID 7682838. S2CID 53256276.
External links
- Atamestane entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.